Efalizumab.

Talamonti M, Spallone G, Di Stefani A, Costanzo A, Chimenti S

Management of secondary hyperparathyroidism in Italy: results of the Italian FARO survey.

Mazzaferro S, Brancaccio D, Messa P, Andreucci VE, Bellinghieri G, Bigazzi R, Bolasco P, Costanzo AM, di Luzio Paparatti U, Cannella G, FARO Study Group

CD28 costimulation regulates FOXP3 in a RelA/NF-κB-dependent mechanism.

Soligo M, Camperio C, Caristi S, Scottà C, Del Porto P, Costanzo A, Mantel PY, Schmidt-Weber CB, Piccolella E

A symphony of regulations centered on p63 to control development of ectoderm-derived structures.

Guerrini L, Costanzo A, Merlo GR

Secondary hyperparathyroidism in chronic dialysis patients: results of the Italian FARO survey on treatment and mortality.

Brancaccio D, Cozzolino M, Cannella G, Messa P, Bonomini M, Cancarini G, Caruso MR, Cascone C, Costanzo AM, di Luzio Paparatti U, Mazzaferro S, FARO Study Group

Patients with moderate to severe plaque psoriasis: one year after the European Medicines Agency recommendation of efalizumab suspension.

Talamonti M, Teoli M, Botti E, Spallone G, Chimenti S, Costanzo A

Psoriasis: from pathogenesis to novel therapeutic approaches.

Monteleone G, Pallone F, MacDonald TT, Chimenti S, Costanzo A

[Renal artery aneurysm. Treatment by ex-vivo reconstruction and autotransplantation: three cases and literature review].

Gabrielli R, Rosati MS, Irace L, Siani A, Vitale S, Millarelli M, Costanzo A, Marcucci G

Our experience of popliteal vein aneurysm.

Gabrielli R, Vitale S, Costanzo A, Carra A

New fluoro derivatives of the pyrazolo[5,1-c][1,2,4]benzotriazine 5-oxide system: evaluation of fluorine binding properties in the benzodiazepine site on γ-aminobutyrric acid type A (GABA(A)) receptor. Design, synthesis, biological, and molecular modeling investigation.

Guerrini G, Ciciani G, Bruni F, Selleri S, Guarino C, Melani F, Montali M, Daniele S, Martini C, Ghelardini C, Norcini M, Ciattini S, Costanzo A